Chase A Cannon1, Meena S Ramchandani1, Susan Buskin2, Julia Dombrowski1,2,3, Matthew R Golden1,2,3. 1. Division of Allergy/Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA. 2. HIV/STD Program, Public Health-Seattle & King County, Seattle, WA; and. 3. Department of Epidemiology, University of Washington, Seattle, WA.
Abstract
BACKGROUND: Preexposure prophylaxis (PrEP) discontinuations are common and are associated with subsequent HIV acquisition. The population-level impact of PrEP discontinuations is unknown. METHODS: Public health staff routinely asked men who have sex with men (MSM) with newly diagnosed HIV infection about their history of PrEP use as part of partner notification interviews in King County, WA, from 2013 to 2021. We assessed trends in the proportion of MSM who ever took PrEP and described reasons for PrEP discontinuation. RESULTS: A total of 1098 MSM were newly diagnosed with HIV during the study period; of whom, 797 (73%) were interviewed, and 722 responded to questions about their history of PrEP use. Ninety-four (13%) reported ever taking PrEP. The proportion of MSM who ever used PrEP before HIV diagnosis increased from 2.3% in 2014 to 26.6% in 2020-2021 ( P < 0.001 for trend). The median time from PrEP discontinuation to HIV diagnosis was 152 days, and median duration on PrEP was 214 days. Common reasons for stopping PrEP included self-assessment as being at low risk for HIV, side effects, and insurance issues. Nineteen men were on PrEP at the time of HIV diagnosis; mutations conferring emtricitabine/tenofovir resistance were identified in 8 (53%) of 15 men with available genotype data. CONCLUSION: More than 25% of MSM with newly diagnosed HIV from 2020 to 2021 had ever used PrEP. More than 50% who discontinued PrEP were diagnosed <6 months after stopping. Strategies to preempt PrEP discontinuations, enhance retention, and facilitate resumption of PrEP are critical to decrease new HIV diagnoses.
BACKGROUND: Preexposure prophylaxis (PrEP) discontinuations are common and are associated with subsequent HIV acquisition. The population-level impact of PrEP discontinuations is unknown. METHODS: Public health staff routinely asked men who have sex with men (MSM) with newly diagnosed HIV infection about their history of PrEP use as part of partner notification interviews in King County, WA, from 2013 to 2021. We assessed trends in the proportion of MSM who ever took PrEP and described reasons for PrEP discontinuation. RESULTS: A total of 1098 MSM were newly diagnosed with HIV during the study period; of whom, 797 (73%) were interviewed, and 722 responded to questions about their history of PrEP use. Ninety-four (13%) reported ever taking PrEP. The proportion of MSM who ever used PrEP before HIV diagnosis increased from 2.3% in 2014 to 26.6% in 2020-2021 ( P < 0.001 for trend). The median time from PrEP discontinuation to HIV diagnosis was 152 days, and median duration on PrEP was 214 days. Common reasons for stopping PrEP included self-assessment as being at low risk for HIV, side effects, and insurance issues. Nineteen men were on PrEP at the time of HIV diagnosis; mutations conferring emtricitabine/tenofovir resistance were identified in 8 (53%) of 15 men with available genotype data. CONCLUSION: More than 25% of MSM with newly diagnosed HIV from 2020 to 2021 had ever used PrEP. More than 50% who discontinued PrEP were diagnosed <6 months after stopping. Strategies to preempt PrEP discontinuations, enhance retention, and facilitate resumption of PrEP are critical to decrease new HIV diagnoses.
Authors: Roger Chou; Christopher Evans; Adam Hoverman; Christina Sun; Tracy Dana; Christina Bougatsos; Sara Grusing; P Todd Korthuis Journal: JAMA Date: 2019-06-11 Impact factor: 56.272
Authors: Julia L Marcus; Leo B Hurley; Charles Bradley Hare; Dong Phuong Nguyen; Tony Phengrasamy; Michael J Silverberg; Juliet E Stoltey; Jonathan E Volk Journal: J Acquir Immune Defic Syndr Date: 2016-12-15 Impact factor: 3.731
Authors: Julia E Hood; David A Katz; Amy B Bennett; Susan E Buskin; Julia C Dombrowski; Stephen E Hawes; Matthew R Golden Journal: Am J Public Health Date: 2017-10-19 Impact factor: 9.308
Authors: Jason Zucker; Caroline Carnevale; Paul Richards; Jacek Slowikowski; Alexander Borsa; Felix Gottlieb; Isabella Vakkur; Christel Hyden; Susan Olender; Alwyn Cohall; Peter Gordon; Magdalena E Sobieszczyk Journal: J Acquir Immune Defic Syndr Date: 2019-08-01 Impact factor: 3.731
Authors: Andrew E Grulich; Rebecca Guy; Janaki Amin; Fengyi Jin; Christine Selvey; Jo Holden; Heather-Marie A Schmidt; Iryna Zablotska; Karen Price; Bill Whittaker; Kerry Chant; Craig Cooper; Scott McGill; Barbara Telfer; Barbara Yeung; Gesalit Levitt; Erin E Ogilvie; Nila J Dharan; Mohamed A Hammoud; Stefanie Vaccher; Lucy Watchirs-Smith; Anna McNulty; David J Smith; Debra M Allen; David Baker; Mark Bloch; Rohan I Bopage; Katherine Brown; Andrew Carr; Christopher J Carmody; Kym L Collins; Robert Finlayson; Rosalind Foster; Eva Y Jackson; David A Lewis; Josephine Lusk; Catherine C O'Connor; Nathan Ryder; Emanuel Vlahakis; Phillip Read; David A Cooper Journal: Lancet HIV Date: 2018-10-17 Impact factor: 12.767
Authors: Patrick S Sullivan; Farah Mouhanna; Robertino Mera; Elizabeth Pembleton; Amanda D Castel; Chandni Jaggi; Jeb Jones; Michael R Kramer; Pema McGuinness; Scott McCallister; Aaron J Siegler Journal: Ann Epidemiol Date: 2020-01-13 Impact factor: 3.797
Authors: Julia L Marcus; Leo B Hurley; Dong Phuong Nguyen; Michael J Silverberg; Jonathan E Volk Journal: Clin Infect Dis Date: 2017-10-30 Impact factor: 9.079
Authors: Philip A Chan; Leandro Mena; Rupa Patel; Catherine E Oldenburg; Laura Beauchamps; Amaya G Perez-Brumer; Sharon Parker; Kenneth H Mayer; Matthew J Mimiaga; Amy Nunn Journal: J Int AIDS Soc Date: 2016-06-13 Impact factor: 5.396
Authors: Zoë R Greenwald; Mathieu Maheu-Giroux; Jason Szabo; Judith Alexia B Robin; Michel Boissonnault; Vinh-Kim Nguyen; Réjean Thomas Journal: BMJ Open Date: 2019-06-27 Impact factor: 2.692